Program 60: Cancer Risk, Prevention, and Early Detection

癌症风险，预防和早期检测计划 项目总结/摘要 癌症风险、预防和早期发现（CaRPED）计划的使命是减少 （a）围绕癌症发生的关键时期开展广泛的研究， 早期生长，和（B）设计临床有效的策略以在风险人群中阻断该过程。的 该计划的范围从一般人群到高危人群，再到患有癌前病变的个人。 病变或靶向突变。 CaRPED是一个新的计划，从以前的癌症风险和差异计划（CaRD）演变而来。其 使命依赖于利用DF/HCC在癌症生物学、流行病学、预防和治疗科学方面的专业知识。 实施，以及波士顿技术创新生态系统的广度和深度。的 该计划致力于将科学进步和知识传播转化为 可持续的社区实践以及减轻与癌症相关的差异。培养新 培养具有跨学科、定量、临床、技术和实施技能的研究人员 这是一个重要的计划重点。 我们的86名成员（55名小学和31名中学）代表了所有七所DF/HCC机构和17所学术机构 部门2019年，该计划的同行评审赠款资金为570万美元的直接成本 来自NCI和其他赞助商的670万美元。在本供资期间，主要的CaRPED 委员发表了914篇与癌症有关的论文。其中，23%是机构间的，9%是机构内的， 43%是两个或两个以上DF/HCC成员之间的项目间合作。 这些数字反映了由计划和高级DF/HCC管理的计划间互动的广度 领导人密切配合癌症中心的战略计划。 对于下一个CCSG资助期，该计划的具体目标是：1）开发和验证新的 癌前和早期癌症检测技术，2）开发个性化和精确的方法， 利用风险评估和癌前和早期癌症检测的新技术进行癌症拦截， 以及3）通过多学科团队应用个性化和精确的癌症拦截方法。 DF/HCC广泛的跨学科合作基础设施，创新的临床试验，社区 参与、共享资源、教育和培训将有助于实现这些具体目标。

Cancer Risk, Prevention, and Early Detection Program Project Summary / Abstract The mission of the Cancer Risk, Prevention, and Early Detection (CaRPED) Program is to decrease the burden of cancer by (a) focusing a broad array of research around the critical period of cancer initiation and early growth, and (b) devising clinically effective strategies to intercept this process among people at risk. The Program’s scope ranges from the general population to high-risk groups to individuals with pre-cancerous lesions or targetable mutations. CaRPED is a new Program that evolved from a previous Program in Cancer Risk and Disparities (CaRD). Its mission relies on leveraging DF/HCC expertise in cancer biology, epidemiology, prevention, and the science of implementation, together with the breadth and depth of the Boston ecosystem for technological innovation. The Program is committed to the translation of scientific advances and the dissemination of knowledge into sustainable community-based practices as well as the alleviation of cancer-related disparities. Training a new generation of researchers with transdisciplinary, quantitative, clinical, technological, and implementation skills is an important Program focus. Our 86 members (55 primary and 31 secondary) represent all seven DF/HCC institutions and 17 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $5.7 million in direct costs from the NCI and $6.7 million from other sponsors. During the current funding period, primary CaRPED members published 914 cancer-relevant papers. Of these, 23% were inter-institutional, 9% were intra- programmatic, and 43% were inter-programmatic collaborations between two or more DF/HCC members. These numbers reflect the breadth of inter-Program interactivity stewarded by Program and senior DF/HCC leaders in close alignment with the Cancer Center’s strategic plan. For the next CCSG funding period, the Program’s Specific Aims are to 1) develop and validate new technologies for pre-cancer and early cancer detection, 2) develop personalized and precision approaches for cancer interception using new technologies for risk assessment and pre-cancer and early cancer detection, and 3) apply personalized and precision approaches for cancer interception through multidisciplinary teams. DF/HCC’s extensive infrastructure for transdisciplinary collaboration, innovative clinical trials, community engagement, shared resources, education, and training will be instrumental in achieving these concrete goals.